



## Teleconference/Webcast: Investor Briefing

**June 29, 2009 – Sydney, Australia, Auckland, New Zealand– Living Cell Technologies Limited (ASX: LCT; OTCQX: LVCLY)** will host a company update teleconference on Tuesday 30 June at 11:00am Australian Eastern Standard Time.

LCT CEO Dr Paul Tan will be joined by the Chief Medical Officer Bob Elliott to provide a clinical and regulatory update following approval by the New Zealand Government to commence a human clinical trial last week.

To participate, please refer to the dial in and web access details below.

### Webcast details

#### Telephone access (toll free) details are below:

1800 131 617	Australia Free Call
+61 7 3107 0222	International / Metered Number
0800 446 958	New Zealand Free Call
800 120 4406	Singapore Free Call
800 962 283	Hong Kong Free Call
001 803 011 4106	Indonesia Free Call
0044 22 132 558	Japan Free Call
866 746 2596	USA/Canada Free Call
0800 376 8339	UK Free Call
0800 330 2094	Germany Free Call
0805 111 476	France Free Call
0800 001 230	Switzerland Free Call

**Online:** <http://services.choruscall.com/links/lct090630.html>

If you would like to dial-in from other locations please contact Paul Dekkers on [pdekkers@bcg.com.au](mailto:pdekkers@bcg.com.au) for details.

-Ends-



**For further information:**

Dr. Paul Tan  
Chief Executive Officer  
Mob: 0402 716 984 (AUS)  
Mob: 021 608 784 (NZ)  
Tel: +64 9 270 794

Mr John Cowan  
Finance & Administration Manager  
Tel: +64 9 276 2690  
[jcowan@lctglobal.com](mailto:jcowan@lctglobal.com)

Prof. Bob Elliott  
Medical Director  
Mob: +64 27 292 4177  
Tel: +64 9 276 2690  
[relliott@lctglobal.com](mailto:relliott@lctglobal.com)

Rebecca Wilson  
Investor and Media Relations (ANZ)  
Mob: +61 417 382 391  
Tel: +61 3 9866 4722  
[rwilson@bcg.com.au](mailto:rwilson@bcg.com.au)

**About Living Cell Technologies:** [www.lctglobal.com](http://www.lctglobal.com)

*Living Cell Technologies (LCT) is developing cell-based products to treat life threatening human diseases. The Company owns a biocertified pig herd that it uses as a source of cells for treating diabetes and neurological disorders. For patients with type 1 diabetes, the Company transplants microencapsulated islet cells so that near-normal blood glucose levels may be achieved without the need for administration of insulin or at significantly reduced levels. The company entered clinical trials for its diabetes product in 2007. For Parkinson's disease, Huntington's disease and other neurological disorders, the company is developing microencapsulated choroid plexus cells that deliver beneficial proteins and neurotrophic factors to the brain. LCT's technology enables healthy living cells to be injected into patients to replace or repair damaged tissue without requiring the use of immunosuppressive drugs to prevent rejection. LCT also offers medical-grade porcine-derived products for the repair and replacement of damaged tissues, as well as for research and other purposes.*

**LCT Disclaimer**

This document contains certain forward-looking statements, relating to LCT's business, which can be identified by the use of forward-looking terminology such as "promising," "plans," "anticipated," "will," "project," "believe," "forecast," "expected," "estimated," "targeting," "aiming," "set to," "potential," "seeking to," "goal," "could provide," "intends," "is being developed," "could be," "on track," or similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no assurance that any existing or future regulatory filings will satisfy the FDA's and other health authorities' requirements regarding any one or more product candidates nor can there be any assurance that such product candidates will be approved by any health authorities for sale in any market or that they will reach any particular level of sales. In particular, management's expectations regarding the approval and commercialisation of the product candidates could be affected by, among other things, unexpected clinical trial results, including additional analysis of existing clinical data, and new clinical data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our products, product candidates, financial results and business prospects. Should one or more of these risks or uncertainties materialise, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. LCT does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise.